

Resignation of Non-Executive Director – Dr Rachel David

Rhythm Biosciences Ltd (ASX: RHY) (“Rhythm” or the “Company”) advises of a change to its Board of Directors.

The Board of Rhythm wishes to advise that it has today received the resignation of Dr Rachel David as a Non-Executive Director of the Company, effective 28 December 2023.

The Board thankfully acknowledges Dr David for her service and contribution to the Company since her appointment just over two years ago (13 December 2021). Dr David expressed a lack of capacity to manage the current requirements of the Company, given extracurricular events of recent times and other corporate roles and responsibilities. It should be noted Dr David, retains a demanding full-time executive position, as Chief Executive Officer of Private Healthcare Australia.

The Company wishes Dr David well in her future endeavours. Dr David, commented...

“I am a strong believer in the technology and an advocate for any improvements in the diagnosis and treatment of cancer...I have greatly enjoyed working with the team and I have enjoyed the opportunity”.

Rhythm will keep the market notified of plans for its future Board composition.

- ENDS -

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via investor@rhythmbio.com or on +61 3 8256 2880:

Mr. Otto Buttula Executive Chairman	Ms. Andrea Steele General Counsel & Company Secretary
---	---

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and Twitter.

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable.

The ColoSTAT® Test-Kit is Rhythm Bioscience’s simple blood test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood presence of CRC. The test can be used as an alternative for individuals who are unable or unwilling to participate in current screening programs.

The ColoSTAT® Test-Kit is based on research from Australia’s CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

Rhythm Biosciences Ltd
ACN 619 459 335
ASX: RHY

www.rhythmbio.com

Australian Registered Address
Bio21 Molecular Science & Biotechnology Institute
30 Flemington Road
Parkville VIC 3010 Australia

T +61 3 8256 2880
E info@rhythmbio.com

Directors
Otto Buttula
Sue MacLeman
Trevor Lockett
Louis Panaccio

Executive Chairman
Independent Deputy Chair
Non-Executive Director
Non-Executive Director